Background: The study aims to collect real-world data on treatment patterns and decision points for treatment in patients with coronary artery disease (CAD) and/ or peripheral artery disease (PAD) treated with rivaroxaban 2.5 mg [twice daily] for the prevention of major cardiovascular events in adult patients with CAD at high risk of ischemic events and/ or documented PAD and to describe outcomes of an antithrombotic regime based on dual pathway inhibition (vascular dose of rivaroxaban 2.5 mg [twice daily] plus low-dose ASA [once daily]) across the broad range of patient risk profiles encountered in routine clinical practice. Sponsor: Bayer Trial Registration No: NCT03746275 ( Link Trial Status: Recruitment stopped Enrolling Centers: Worldwide: 5841 Participants Core Study Team:
© Christian Mueller, 2012 - 2024 │ DisclaimerImprintWebmaster │ Last Update: June 2024
Ina-Maria Ferel, Ph.D. Prof. Christian Müller Prof. Otmar Pfister Dr. Thilo Burkard